Bionano Genomics- Warrants (21/08/2023) Operating Income

As of the most recent data (June 2026), BNGOW shows a operating income of $-32M. That compares with $-72M in the prior-year period — up 55.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BNGOW's operating income is now $-32M (was $-72M) — a 55.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Bionano Genomics- Warrants (21/08/2023) is outperforming or lagging.

Tracking BNGOW's operating income over time shows whether Bionano Genomics- Warrants (21/08/2023) is scaling, shrinking, or reshaping that part of the business. The current reading is $-32M That compares with $-72M in the prior-year period — up 55.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Bionano Genomics- Warrants (21/08/2023)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-32M) with ownership activity and broader fundamentals.

Bionano Genomics- Warrants (21/08/2023)'s operating income is $-32M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.